HMGB1 and colorectal cancer: Our primary objective in this study was to design an oncolytic HSV expressing HMGB1 to kill colorectal cancer cell lines, in particular during hypoxia; however, HSV-HMGB1 failed to destroy HT29 cells at MOI 0.1 under hypoxic conditions.